![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically Relevant Drug-Drug Interaction With Either Cyclosporine or Tacrolimus
|
|
|
Reported by Jules Levin, AASLD 2013 Nov 1-5 Wash DC
Bifano M,1 Adamczyk R,1 Hwang C,1 Kandoussi H,2 Marion A,3 Bertz RJ1
1Bristol-Myers Squibb, Hopewell, NJ; 2Bristol-Myers Squibb, Lawrenceville, NJ; 3ICON Development Solutions, Omaha, NE
Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C - (11/25/13)
Drug-drug interactions with oral anti-HCV agents and Idiosyncratic Hepatotoxicity in the Liver Transplant setting - (11/25/13)
![AASLD1.gif](../images/120113/120213-6/AASLD1.gif)
![AASLD2.gif](../images/120113/120213-6/AASLD2.gif)
![AASLD4.gif](../images/120113/120213-6/AASLD4.gif)
![AASLD5.gif](../images/120113/120213-6/AASLD5.gif)
![AASLD6.gif](../images/120113/120213-6/AASLD6.gif)
![AASLD7.gif](../images/120113/120213-6/AASLD7.gif)
![AASLD8.gif](../images/120113/120213-6/AASLD8.gif)
![AASLD9.gif](../images/120113/120213-6/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|